{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:34:09Z","timestamp":1772814849074,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.3816\/clm.2009.s.029","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T10:04:58Z","timestamp":1254218698000},"page":"S305-S311","source":"Crossref","is-referenced-by-count":15,"special_numbering":"S3","title":["Red Bood Cell Transfusion Therapy and Iron Chelation in Patients With Myelodysplastic Syndromes"],"prefix":"10.3816","volume":"9","author":[{"given":"Luca","family":"Malcovati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.s.029_bib1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMp048266","article-title":"Myelodysplastic syndromes\u2013coping with ineffective hematopoiesis","volume":"352","author":"Cazzola","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.029_bib2","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V71.2.305.305","article-title":"Natural history of idiopathic refractory sideroblastic anemia","volume":"71","author":"Cazzola","year":"1988","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib4","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria. A basis for clinical decision-making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.029_bib5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2141.1983.tb02145.x","article-title":"Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias","volume":"54","author":"Cazzola","year":"1983","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.029_bib6","first-page":"727","article-title":"Hepcidin and iron-loading anemias","volume":"91","author":"Nemeth","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.029_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3324\/haematol.11705","article-title":"Hepcidin: from discovery to differential diagnosis","volume":"93","author":"Kemna","year":"2008","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.029_bib8","first-page":"809","article-title":"The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major","volume":"91","author":"Kattamis","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.029_bib9","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood-2002-07-2006","article-title":"Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia","volume":"101","author":"Cazzola","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.leukres.2006.06.005","article-title":"Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts)","volume":"31","author":"Steensma","year":"2007","journal-title":"Leuk Res"},{"key":"10.3816\/CLM.2009.s.029_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2141.1982.tb03937.x","article-title":"Erythroblast iron metabolism in sideroblastic marrows","volume":"52","author":"May","year":"1982","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.029_bib12","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2003-07-2446","article-title":"Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome","volume":"103","author":"Gattermann","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib13","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1046\/j.0007-1048.2001.03323.x","article-title":"Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes","volume":"116","author":"Reddy","year":"2002","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.029_bib14","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood-2002-06-1825","article-title":"Mitochondrial DNA mutations in patients with myelodysplastic syndromes","volume":"101","author":"Shin","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib15","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1182\/blood.V106.11.3444.3444","article-title":"Mitochondrial ferritin expression and clonality of hematopoiesis in patients with refractory anemia with ringed sideroblasts","volume":"106","author":"Della Porta","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood-2005-12-4769","article-title":"Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype","volume":"108","author":"Pellagatti","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib17","doi-asserted-by":"crossref","first-page":"e1970","DOI":"10.1371\/journal.pone.0001970","article-title":"The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts","volume":"3","author":"Boultwood","year":"2008","journal-title":"PLoS ONE"},{"key":"10.3816\/CLM.2009.s.029_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3324\/haematol.11581","article-title":"The JAK2-V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"93","author":"Schmitt-Graeff","year":"2008","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.029_bib19","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.029_bib20","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.3816\/CLM.2009.s.029_bib21","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.029_bib22","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMc051878","article-title":"JAK2 mutations in myeloproliferative disorders","volume":"353","author":"Tefferi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.029_bib23","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1182\/blood.V108.11.854.854","article-title":"Granulocyte JAK2 (V617F) mutation status in myeloid neoplasms with ringed sideroblasts","volume":"108","author":"Malcovati","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib24","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life","volume":"120","author":"Hellstrom-Lindberg","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.029_bib25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1365-2141.2003.04272.x","article-title":"Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes","volume":"121","author":"Jansen","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.029_bib26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood-2003-07-2252","article-title":"Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial","volume":"104","author":"Casadevall","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib27","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1182\/blood-2006-10-055384","article-title":"Racial variation in the relationship of anemia with mortality and mobility disability among older adults","volume":"109","author":"Patel","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib28","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1056\/NEJMoa010615","article-title":"Blood transfusion in elderly patients with acute myocardial infarction","volume":"345","author":"Wu","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.029_bib29","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.leukres.2005.03.004","article-title":"Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndromes","volume":"29","author":"Oliva","year":"2005","journal-title":"Leuk Res"},{"key":"10.3816\/CLM.2009.s.029_bib30","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.029_bib31","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ajh.21249","article-title":"International MDS risk analysis workshop (IMRAW)\/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes","volume":"83","author":"Kao","year":"2008","journal-title":"Am J Hematol"},{"key":"10.3816\/CLM.2009.s.029_bib32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1034\/j.1600-0609.2000.065005297.x","article-title":"Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88","volume":"65","author":"Nilsson-Ehle","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2009.s.029_bib33","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2005-07-3046","article-title":"The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?","volume":"107","author":"Beutler","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib34","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib35","first-page":"1286","article-title":"Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology","volume":"87","author":"Alessandrino","year":"2002","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.029_bib36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.03907.x","article-title":"Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes","volume":"120","author":"Bowen","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.029_bib37","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.029_bib38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib39","first-page":"1588","article-title":"Predicting survival and leukemic evolution in patients with myelodysplastic syndrome","volume":"91","author":"Malcovati","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.029_bib40","first-page":"723a","article-title":"A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes","volume":"110","author":"Della Porta","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib41","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2008-03-143735","article-title":"WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"112","author":"Alessandrino","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib42","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"J\u00e4dersten","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.029_bib43","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","article-title":"Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience","volume":"111","author":"Park","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1749-6632.1998.tb10475.x","article-title":"Pathophysiology of iron overload","volume":"850","author":"Hershko","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.3816\/CLM.2009.s.029_bib45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM198102053040603","article-title":"Clinical consequences of acquired transfusional iron overload in adults","volume":"304","author":"Schafer","year":"1981","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.029_bib46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0002-9343(71)90240-3","article-title":"Iron in the heart. Etiology and clinical significance","volume":"51","author":"Buja","year":"1971","journal-title":"Am J Med"},{"key":"10.3816\/CLM.2009.s.029_bib47","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3324\/haematol.12759","article-title":"Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias","volume":"93","author":"Di Tucci","year":"2008","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.029_bib48","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2006-10-054924","article-title":"Prognostic impact of elevated pre-transplant serum ferritin in patients undergoing myeloablative stem cell transplantation","volume":"109","author":"Armand","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib49","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM200008033430503","article-title":"Hepatic iron concentration and total body iron stores in thalassemia major","volume":"343","author":"Angelucci","year":"2000","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.029_bib50","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199409013310903","article-title":"Survival in medically treated patients with homozygous beta-thalassemia","volume":"331","author":"Olivieri","year":"1994","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.029_bib51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2001.03195.x","article-title":"Practical management of iron overload","volume":"115","author":"Porter","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.029_bib52","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1046\/j.1365-2141.2003.04297.x","article-title":"Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry","volume":"121","author":"Fischer","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.029_bib53","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1053\/euhj.2001.2822","article-title":"Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload","volume":"22","author":"Anderson","year":"2001","journal-title":"Eur Heart J"},{"key":"10.3816\/CLM.2009.s.029_bib54","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","article-title":"Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia","volume":"360","author":"Anderson","year":"2002","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.029_bib55","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2141.2007.06695.x","article-title":"Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions","volume":"138","author":"Chacko","year":"2007","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.029_bib56","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ajh.20980","article-title":"No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique","volume":"82","author":"Konen","year":"2007","journal-title":"Am J Hematol"},{"key":"10.3816\/CLM.2009.s.029_bib57","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.029_bib58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s002770050236","article-title":"Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial","volume":"73","author":"Kersten","year":"1996","journal-title":"Ann Hematol"},{"key":"10.3816\/CLM.2009.s.029_bib59","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.029_bib60","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0609.2007.00985.x","article-title":"Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study","volume":"80","author":"Porter","year":"2008","journal-title":"Eur J Haematol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T20:39:17Z","timestamp":1710621557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":60,"alternative-id":["S1557919011703572"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.s.029","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}